Search
Enrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedEnrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use. Due to the identification of fluoroquinolone-resistant strains of Campylob...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsFenbendazole
go.drugbank.com/drugs/DB11410InvestigationalVet approvedFenbendazole is a benzimidazole that presents a wide spectrum anthelmintic effect. It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, ae...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesTechnetium Tc-99m tetrofosmin
go.drugbank.com/drugs/DB09160ApprovedTechnetium Tc-99m tetrofosmin is a drug used in nuclear myocardial perfusion imaging. The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and w...
Categories: P-glycoprotein substratesEtizolam
go.drugbank.com/drugs/DB09166InvestigationalEtizolam is a thienodiazepine which is chemically related to benzodiazepine (BDZ) drug class; it differs from BDZs in having a benzene ring replaced with a thiophene ring. It is an agonist at GABA-A receptors and possesses amnesic, anxio...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesButyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicitButyrfentanyl or butyrylfentanyl (not to be confused with 3-methylfentanyl) is a potent short-acting synthetic opioid analgesic drug. It is an analog of fentanyl with roughly 1/30 the potency. Butyrfentanyl was first synthesized in 1961 ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesRivoglitazone
go.drugbank.com/drugs/DB09200InvestigationalRivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsAzelnidipine
go.drugbank.com/drugs/DB09230InvestigationalAzelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNiguldipine
go.drugbank.com/drugs/DB09239ExperimentalNiguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesNiludipine
go.drugbank.com/drugs/DB09240ExperimentalNiludipine is a calcium channel blocker.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalLumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused ...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducers